Birkeland S A, Hamilton-Dutoit S, Bendtzen K
Department of Nephrology, Odense University Hospital, Odense, Denmark.
Transplantation. 2003 Jul 15;76(1):153-8. doi: 10.1097/01.TP.0000072015.08302.E9.
Posttransplant lymphoproliferative disorder (PTLD) can be resolved in many transplant patients by the reduction or cessation of immunosuppression, after which many grafts continue to function as the result of a form of operational tolerance. When graft function deteriorates, retransplantation may be an option. Cytokines such as interleukin (IL)-10 and IL-18 may play a role in PTLD tolerance induction and tumor regression. We report long-term follow-up on the duration of graft tolerance and the course of retransplantation in a series of patients who underwent kidney transplantation and demonstrated PTLD, and in whom we were able to perform IL-18 analyses.
Patients were followed for up to 7 years after PTLD diagnosis. Treatment consisted of immunosuppression cessation with radiation therapy in cases with overt monomorphic lymphomas. All patients' PTLDs were resolved, and all patients but one (whose graft was removed) demonstrated a period of operational graft tolerance of up to 5 years. Five patients underwent retransplantation without sign of recurrence of the PTLD up to 3 years after transplantation. In the eight patients analyzed, IL-18 increased significantly during PTLD regression and follow-up in those with long-term operational tolerance.
We report on a series of patients with resolved PTLDs demonstrating long-term recurrence-free survival, of whom most experienced a long period of operational graft tolerance. IL-18 seems to play a role in the resolution of the PTLDs. Five patients underwent retransplantation with standard immunosuppression without recurrence. A previous diagnosis of PTLD should not be regarded as a contraindication for later retransplantation.
许多移植患者的移植后淋巴细胞增生性疾病(PTLD)可通过减少或停用免疫抑制来解决,之后许多移植物因一种操作性耐受形式而继续发挥功能。当移植物功能恶化时,再次移植可能是一种选择。细胞因子如白细胞介素(IL)-10和IL-18可能在PTLD耐受诱导和肿瘤消退中发挥作用。我们报告了一系列接受肾移植并发生PTLD且能够进行IL-18分析的患者移植物耐受持续时间和再次移植过程的长期随访情况。
患者在PTLD诊断后随访长达7年。对于明显的单形性淋巴瘤患者,治疗包括停用免疫抑制并联合放射治疗。所有患者的PTLD均得到缓解,除1例(其移植物被切除)外,所有患者均表现出长达5年的操作性移植物耐受期。5例患者接受了再次移植,移植后3年内无PTLD复发迹象。在分析的8例患者中,IL-18在PTLD消退期间及长期具有操作性耐受的患者随访期间显著升高。
我们报告了一系列PTLD得到缓解且显示长期无复发生存的患者,其中大多数经历了较长时间的操作性移植物耐受。IL-18似乎在PTLD的消退中发挥作用。5例患者在标准免疫抑制下接受再次移植且无复发。既往PTLD诊断不应被视为后期再次移植的禁忌证。